230 related articles for article (PubMed ID: 11235955)
1. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
[TBL] [Abstract][Full Text] [Related]
3. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
[TBL] [Abstract][Full Text] [Related]
4. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
Divisova J; Kuiatse I; Lazard Z; Weiss H; Vreeland F; Hadsell DL; Schiff R; Osborne CK; Lee AV
Breast Cancer Res Treat; 2006 Aug; 98(3):315-27. PubMed ID: 16541323
[TBL] [Abstract][Full Text] [Related]
5. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.
Muller AF; Janssen JA; Lamberts SW; Bidlingmaier M; Strasburger CJ; Hofland L; van der Lely AJ
Clin Endocrinol (Oxf); 2001 Oct; 55(4):461-7. PubMed ID: 11678828
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist.
Friend KE; Radinsky R; McCutcheon IE
J Neurosurg; 1999 Jul; 91(1):93-9. PubMed ID: 10389886
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
8. GH receptor blocker administration and muscle-tendon collagen synthesis in humans.
Nielsen RH; Doessing S; Goto K; Holm L; Reitelseder S; Agergaard J; Schjerling P; Flyvberg A; Kjaer M
Growth Horm IGF Res; 2011 Jun; 21(3):140-5. PubMed ID: 21498100
[TBL] [Abstract][Full Text] [Related]
9. Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD).
Berg CA; Pokrajac A; Bidlingmaier M; Strasburger CJ; Shalet SM; Trainer PJ
Clin Endocrinol (Oxf); 2009 Mar; 70(3):439-45. PubMed ID: 19067728
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model.
Evans A; Jamieson SM; Liu DX; Wilson WR; Perry JK
Cancer Lett; 2016 Aug; 379(1):117-23. PubMed ID: 27241667
[TBL] [Abstract][Full Text] [Related]
11. Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome.
Akintoye SO; Kelly MH; Brillante B; Cherman N; Turner S; Butman JA; Robey PG; Collins MT
J Clin Endocrinol Metab; 2006 Aug; 91(8):2960-6. PubMed ID: 16720661
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone (GH) activity is associated with increased serum oestradiol and reduced anti-Müllerian hormone in healthy male volunteers treated with GH and a GH antagonist.
Andreassen M; Frystyk J; Faber J; Kristensen LØ; Juul A
Andrology; 2013 Jul; 1(4):595-601. PubMed ID: 23785020
[TBL] [Abstract][Full Text] [Related]
13. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men.
Veldhuis JD; Bidlingmaier M; Anderson SM; Evans WS; Wu Z; Strasburger CJ
J Clin Endocrinol Metab; 2002 Dec; 87(12):5737-45. PubMed ID: 12466380
[TBL] [Abstract][Full Text] [Related]
14. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
[TBL] [Abstract][Full Text] [Related]
15. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.
Muller AF; Leebeek FW; Janssen JA; Lamberts SW; Hofland L; van der Lely AJ
J Clin Endocrinol Metab; 2001 Nov; 86(11):5165-71. PubMed ID: 11701672
[TBL] [Abstract][Full Text] [Related]
16. Cancer and the potential place for growth hormone receptor antagonist therapy.
Friend KE
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S121-3. PubMed ID: 11527083
[TBL] [Abstract][Full Text] [Related]
17. Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant.
Roemmler J; Bidlingmaier M; Schopohl J
Pituitary; 2010; 13(1):89-93. PubMed ID: 18498055
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
19. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
[TBL] [Abstract][Full Text] [Related]
20. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
Zgliczyński W; Zdunowski P
Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
